BAYRY BAYER AG S/ADR Loading... : Bullish and Bearish Analyst Opinions

Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
All Content
Source feeds
Buzzberg Top 50
All market capsNo capitalization filter
200 B and aboveMega
10 B to 200 BLarge
2 B to 10 BMid
0 to 2 BSmall
Custom
Enter market cap range in B USD
All directions
▲ Long
▼ Short
⛔ Avoid
✂ Close
◦ Others
Any score
LOW+
MED+
HIGH
? ?
08:36
Jul 02
Bloomberg Newswire (@business)
Bayer is placing its US glyphosate business into a newly formed entity called Ruveon according.
Bayer is placing its US glyphosate business into a newly formed entity called Ruveon according to the report.
18:40
Jun 25
Bloomberg Newswire (@business)
Bayer secures a major legal victory in the Supreme Court over Roundup weedkiller lawsuits after.
Bayer secures a major legal victory in the Supreme Court over Roundup weedkiller lawsuits after years of costly setbacks.
14:01
Jun 25
zerohedge Financial blog / news aggregator
Supreme Court ruling shields Bayer from Roundup cancer-warning lawsuits.
Supreme Court ruling shields Bayer from Roundup cancer-warning lawsuits, removing a major legal liability.
17:40
Jun 23
FirstSquawk Newswire (@FirstSquawk)
Eli Lilly and Bayer criticize Germany's spending on innovative medicines.
Eli Lilly and Bayer criticize Germany's spending on innovative medicines, warning current policies could undermine pharmaceutical investment attractiveness, as reported by the Financial Times.
05:44
Jun 12
Bloomberg Newswire (@business)
Bayer shares face a make-or-break few weeks with two upcoming court developments key.
Bayer shares face a make-or-break few weeks with two upcoming court developments key to stemming a wipeout in market value.
08:30
Jun 01
Reuters Business Newswire (@ReutersBiz)
Bayer's Monsanto debacle is analyzed in a Breakingviews column highlighting bitter M&A lessons.
Bayer's Monsanto debacle is analyzed in a Breakingviews column highlighting bitter M&A lessons from the acquisition.
06:15
Jun 01
Reuters Business Newswire (@ReutersBiz)
Bayer's Monsanto debacle is analyzed in a Breakingviews column highlighting bitter M&A lessons.
Bayer's Monsanto debacle is analyzed in a Breakingviews column highlighting bitter M&A lessons from the acquisition.
13:00
May 06
Chuck Magro CEO, Corteva, Inc. CTVA Q1 FY26 call
The Bayer licensing agreement is driving stronger-than-expected demand for Corteva's seed technology, positioning the company to become royalty positive ahead of schedule.
BAYRY
HIGH
17:14
Mar 04
Bayer said a US judge granted preliminary approval for its $7.25 billion settlement proposal.
Bayer said a US judge granted preliminary approval for its $7.25 billion settlement proposal aimed at containing its liability from thousands of lawsuits over Roundup weedkiller, which have weighed on the German company for years. https://t.co/3PGGrHg0vV
16:36
Feb 26
Positive Phase 3 trial data for a key drug combination is a significant fundamental catalyst.
Positive Phase 3 trial data for a key drug combination is a significant fundamental catalyst that should drive the stock price higher.
BAYRY
MED
21:43
Feb 18
Bayer faces significant headwinds as its Roundup settlement is met with skepticism.
Bayer faces significant headwinds as its Roundup settlement is met with skepticism, coupled with a direct company warning of negative cash flow and ongoing litigation risk.
BAYRY
MED
14:00
Feb 04
Chuck Magro CEO, Corteva, Inc. CTVA Q4 FY25 call
Bayer settlement accelerates Corteva's corn licensing to 2027 (5 years early) and introduces cotton licensing, with a $1B EBITDA upside over 10 years. — Opens new revenue streams for Corteva and potentially increases competitive pressure on Bayer's seed businesses.
BAYRY
HIGH
13:30
Jan 30
Chris Fethmore CFO, Regeneron Pharmaceuticals, Inc. REGN Q4 FY25 call
Bayer collaboration on Eylea products remains a substantial source of international revenue and profit.
BAYRY
HIGH
08:30
Jan 29
Mark Casper Chairman, President, and CEO, Thermo Fisher Scientific Inc TMO Q4 FY25 call
Thermo Fisher's Oncomind DX test was FDA-approved as a companion diagnostic for Bayer's therapy, strengthening Bayer's targeted lung cancer treatment and driving demand for Thermo Fisher's NGS diagnostics.
BAYRY
HIGH

About BAYRY Analyst Coverage

Buzzberg tracks BAYRY (BAYER AG S/ADR) across 5 sources. 0 bullish vs 0 bearish calls from 9 analysts. Sentiment: evenly split. 14 total trade ideas tracked. Latest voices: Bloomberg, zerohedge, FirstSquawk.